Cargando…
SAT409 Sublingual Estradiol Only, Compared To Combined Oral Estradiol And Cyproterone Acetate,Offers No Apparent Advantage For Gender Affirming Hormone Therapy (GHAT), In Treatment Naïve Transwomen: Results Of A Prospective Pilot Study
Disclosure: I. Yaish: None. G. Gindis: None. Y. Greenman: None. G. Shefer: None. A. Buch: None. M. Arbiv: None. Y. Moshe: None. Y. Sofer: None. K.M. Tordjman: None. Background: The standard approach for Gender-Affirming Hormone Therapy (GAHT) oftransgender women (TW) in Israel is oral estradiol (OE)...
Autores principales: | Yaish, Iris, Gindis, Guy, Greenman, Yona, Shefer, Gabi, Buch, Assaf, Arbiv, Mira, Moshe, Yaffa, Sofer, Yael, Tordjman, Karen Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554417/ http://dx.doi.org/10.1210/jendso/bvad114.2080 |
Ejemplares similares
-
SAT394 Over-representation Of Adoptees Among Transgender Subjects Seeking Gender-Affirming-Hormonal-Therapy (GAHT) In A Large Tertiary Medical Center
por: Yaish, Iris, et al.
Publicado: (2023) -
SAT391 Supratherapeutic Estrogen Levels in Transgender Women Likely From Sublingual Estradiol
por: Jalal, Erica, et al.
Publicado: (2023) -
SAT406 Evaluation Of The Emotional And Cognitive Effects Of Hormone Therapy In Transgender Men And Women
por: Yaish, Iris, et al.
Publicado: (2023) -
SAT404 Achieving Both Target Testosterone And Target Estradiol Levels May Not Be Practical In All Trans Feminine Users Of Estradiol - Which To Prioritize?
por: Slack, Daniel, et al.
Publicado: (2023) -
SAT397 A Low Dose Cyproterone Acetate In Feminizing Hormone Treatment
por: Korpaisarn, Sira, et al.
Publicado: (2023)